TK and JPB Co-first; RK, DS, and AMZ are Co-senior authors.

Introduction

MDS with TP53 mutations ( TP53 MT) are associated with high-risk disease features and rapid progression to AML. Effective treatment for this aggressive subtype is still not available. As compared to monoallelic TP53 MT, biallelic MT have been associated with adverse outcomes and worse overall survival (OS), but the impact of allelic status on treatment response and OS after HMA therapy are not well established. In this study, we analyzed TP53 allelic state for a large well annotated cohort of pts with MDS who were treated with HMAs.

Methods

The VALIDATE database includes pts with MDS treated with frontline HMA from 14 specialized centers. Pts were considered to have biallelic TP53 MT according to the ICC definition (Arber et al. 2022, Blood) if they meet any of the following: a. two TP53 MT (variant allelic frequency [VAF]>10% for each) b. single TP53 MT with copy neutral loss of heterozygosity (CN-LOH, available for 308 pts) c. TP53 MT with del17p and d. Single TP53 MT with VAF >50%. Time to event analyses were estimated using Kaplan-Meier estimator and groups were compared by the log-rank test from the time of HMA initiation. Only higher risk (HR)-MDS pts (IPSS>1 or IPSS-R>3.5) with BM biopsy within 180 days after HMA initiation were assessed for complete response (CR) and overall response rate (ORR) according to the IWG 2023 criteria (Zeidan et al, Blood 2023) (n=480). OS was calculated from time of HMA therapy initiation. This study was supported by an independent research grant from AbbVie.

Results

A total of 816 pts met eligibility and were included in this analysis. Median age was 68 years (IQR: 61-74) and 64% were men. MDS excess blast (EB) 1/2 was the most common MDS subtype (62%). Overall, 78% of the pts were treated with HMA monotherapy (26% decitabine [DEC] and 74% azacitidine [AZA]) and 22% received HMA as part of combination therapy. In total, 40% of the pts underwent allogenic HSCT. Median HMA treatment time was 5 months (mo), IQR:3-11. Median follow up time was 17 mo (IQR:9-31). TP53 MT were detected in 253 pts (31%) at time of MDS diagnosis, of whom 153 (60%) pts had biallelic TP53 MT and 100 (40%) pts had monoallelic TP53 MT. Missense MTs were identified in 80% of pts with monoallelic TP53 MT. TP53 MT/del17p (33%), TP53 MT/CN-LOH (28%), and multiple TP53 MT (25%) were the most common combinations in pts with biallelic TP53 MT. Pts with TP53 MT had higher rates of MDS-EB (74% vs. 61%, p<0.001). Complex karyotype was observed in 112 (73%) pts with biallelic TP53 MT and 81 (81%) pts with monoallelic TP53 MT (p=0.154). Median number of HMA cycles among pts with TP53 MT was 8 (IQR:5-12) and higher compared to pts without TP53 MT (5 cycles, IQR:3-9), p=0.032 ( Panel-A). In a logistic regression model for CR, TP53 MT was not associated with probability of achieving CR (1.4, 0.89-2.29). CR rates for pts with biallelic TP53 MT (18%) and monoallelic TP53 MT (14%) were not significantly different, p=0.37. There were also no significant differences in ORR observed between biallelic TP53 MT (59%) and monoallelic TP53 MT (54%) pts, p=0.39. Among TP53 MTpts treated with HMA monotherapy, pts treated with AZA compared to DEC had similar odds for ORR (OR:1.1, 95%CI: 0.7-1.6)/CR (OR: 0.8, 95%CI: 0.4-1.3) and hazard for OS (HR: 1.1, 0.9-1.4). As expected, the median OS (mo, 95%CI) for pts with TP53 MT (12, 10-13) was significantly lower than pts without TP53 MT (28, 25-31), p<0.001. Importantly, pts with biallelic TP53 MT (11, 9-14) had no significant difference in median OS compared to monoallelic TP53 MT (13, 11-17), p=0.268 (Panel-B). In a multivariable cox proportional hazard regression model for OS (hazards ratio, 95%CI) adjusted for age (1.0, 0.9-1.0), HSCT (0.4, 0.3-0.4), IPSS-M score (1.2, 1.1-1.3), and complex karyotype (1.4, 1.1-1.8), TP53 MT status (1.8, 1.4-2.3) was still associated with OS. However, biallelic TP53 MT had comparable risk to monoallelic TP53 MT (1.2, 0.9-1.7).

Conclusions

To our knowledge, VALIDATE is the largest database of MDS pts with TP53 MT who were treated with HMA. We confirm that TP53 MT have significant negative impact on survival, but not on response to HMA therapy. Importantly, we did not observe OS differences between monoallelic and biallelic TP53 MT. We also show that the type of HMA monotherapy used does not impact outcome of these pts. Overall, pts with TP53 MT have very poor outcomes and are in desperate need of new, effective therapies.

Stahl:Sierra Oncology: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: GME activity ; Rigel: Membership on an entity's Board of Directors or advisory committees; Clinical care options: Other: GME activity ; GSK: Membership on an entity's Board of Directors or advisory committees; Boston Consulting: Consultancy; Kymera: Membership on an entity's Board of Directors or advisory committees; Curis Oncology: Other: GME activity ; Dedham group: Consultancy; Haymarket Media: Other: GME activity . DeZern:Caribou: Membership on an entity's Board of Directors or advisory committees; Geron: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy; Bristol Myers Squibb: Consultancy; Appellis: Consultancy, Membership on an entity's Board of Directors or advisory committees. Sekeres:Geron: Membership on an entity's Board of Directors or advisory committees; Kurome: Consultancy, Current holder of stock options in a privately-held company; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees. Carraway:AbbVie: Other; Daiichi: Consultancy; Astex Pharmaceuticals: Other; Agios: Consultancy, Speakers Bureau; Celgene: Research Funding; Genentech: Consultancy; Stemline Therapeutics: Consultancy, Speakers Bureau; Syndax: Other: DSMB; Jazz Pharmaceuticals: Consultancy, Other: Travel, Accommodations, Expenses , Speakers Bureau; BMS: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy, Other: Travel, Accommodations, Expenses , Speakers Bureau; Takeda: Other. Desai:Janssen Research & Development: Research Funding; Abbvie: Consultancy, Other: Advisory role; BMS: Consultancy, Other: Advisory role; Servier: Consultancy, Other: Advisory role; Janssen Pharmaceuticals: Current Employment. Griffiths:Bristol Myers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Blueprint Medicines, Inc: Research Funding; Astex Pharmaceuticals: Research Funding; CTI Biopharma: Consultancy; AstraZeneca Rare Disease: Consultancy, Research Funding; Genentech, Inc.: Consultancy, Research Funding; MediCom Worldwide, Inc.: Honoraria; Alexion Pharmaceuticals: Consultancy, Research Funding; Abbvie: Consultancy; S. Karger Publishing: Honoraria; Apellis Pharmaceuticals: Consultancy, Research Funding; Medscape: Honoraria; NextCure, Inc: Research Funding; Vera and Joseph Dresner Foundation: Membership on an entity's Board of Directors or advisory committees; Partner Therapeutics: Consultancy; Artis Ventures: Membership on an entity's Board of Directors or advisory committees; American Society of Hematology: Honoraria; Physicians Educational Resource: Honoraria; Taiho Oncology: Consultancy; Takeda Oncology: Consultancy; Picnic Health: Membership on an entity's Board of Directors or advisory committees; Celldex Therapeutics: Research Funding; MDS International Foundation: Honoraria; AAMDSIF: Honoraria. Stein:Agios: Consultancy; OnCusp: Consultancy; Novartis: Consultancy; Servier: Consultancy; Calithera: Consultancy; Syndax: Consultancy; Neoleukin: Consultancy; Abbvie: Consultancy; Genentech: Consultancy; Aptose: Consultancy; Eisai: Research Funding; Bristol Myers Squib: Consultancy, Research Funding; PinotBio: Consultancy; Janssen: Consultancy; Gilead: Consultancy; Foghorn: Consultancy; CTI Biopharma: Consultancy; Jazz: Consultancy; Menarini: Consultancy; Genesis: Consultancy; Daiichi: Consultancy; Syros: Consultancy; Ono Pharma: Consultancy; Astellas: Consultancy; Blueprint: Consultancy. Brunner:AstraZeneca: Research Funding; Taiho: Consultancy; Takeda: Consultancy; Acceleron: Consultancy; Agios: Consultancy, Research Funding; Celgene/BMS: Consultancy, Research Funding; GSK: Research Funding; Janssen: Research Funding; Keros Therapeutics: Consultancy; Novartis: Consultancy, Research Funding; Gilead: Consultancy. Zeidner:Daiichi Sankyo: Honoraria; Foghorn: Consultancy; Immunogen: Honoraria; Gilead: Consultancy, Honoraria, Research Funding; Stemline: Research Funding; Sumitomo Dainippon Pharma: Research Funding; Shattuck Labs: Honoraria, Research Funding; Servier: Consultancy, Honoraria; Sellas: Consultancy; Novartis: Consultancy; Merck: Research Funding; Jazz: Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Arog: Research Funding; Astex: Research Funding; Takeda: Research Funding. Savona:Boehringer Ingelheim: Patents & Royalties; TG Therapeutics, Inc.: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda Pharmaceutical Company: Membership on an entity's Board of Directors or advisory committees, Research Funding; Taiho: Membership on an entity's Board of Directors or advisory committees; Ryvu Therapeutics: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; ALX Oncology: Research Funding; Astex Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Sierra Oncology, Inc.: Membership on an entity's Board of Directors or advisory committees; AbbVie Inc.: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Karyopharm Therapeutics Inc.: Consultancy, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Geron Corporation: Membership on an entity's Board of Directors or advisory committees; CTI BioPharma Corp.: Membership on an entity's Board of Directors or advisory committees; Forma Therapeutics Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees. Singh:Rigel: Other: Advisor or review panel participant. Roboz:AZ: Consultancy; Astellas: Consultancy; AbbVie: Consultancy; Mesoblast: Consultancy; Agios: Consultancy; MEI: Consultancy; Jazz: Consultancy; Actinium: Consultancy; Amgen: Consultancy; Bluebird bio: Consultancy; GSK: Consultancy; Janssen: Consultancy, Research Funding; Jasper: Consultancy; Blueprint: Consultancy; Novartis: Consultancy; BMS: Consultancy; Pfizer: Consultancy; Syndax: Consultancy; Takeda: Consultancy. Wang:Kura Oncology: Speakers Bureau; Dava oncology: Speakers Bureau; Takeda: Consultancy; PharmaEssentia: Consultancy; Pfizer: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Kite: Consultancy, Speakers Bureau; Jazz: Consultancy; GlaxoSmithKline: Consultancy; BMS: Consultancy; Gilead: Consultancy; Astellas: Consultancy, Speakers Bureau; Abbvie: Consultancy. Shallis:Servier: Consultancy; Bristol Myers Squibb: Consultancy; Gilead Sciences: Consultancy; Rigel: Consultancy; Curio Science: Consultancy. Xie:Moffitt Cancer Center: Current Employment; Novartis: Speakers Bureau. Padron:Pharmaessentia: Membership on an entity's Board of Directors or advisory committees; CTI: Membership on an entity's Board of Directors or advisory committees; Gillead: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Incyte: Research Funding; Kura: Research Funding. Maciejewski:Alexion: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Speakers Bureau; Regeneron: Consultancy, Honoraria; Omeros: Consultancy. Della Porta:Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees. Komrokji:AbbVie, CTI biopharma, Jazz, Pharma Essentia, Servio: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Geron: Consultancy; Rigel, Taiho, DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees. Sallman:Aprea, Jazz: Research Funding; AbbVie, Affimed Gmbh, Gilead, Incyte, Intellisphere, LLC, Molecular Partners AG, PGEN Therapeutics, Inc., Takeda, Zentalis; Advisory board for AvenCell, BlueBird Bio, BMS, Intellia, Jasper Therapeutics, Kite, Magenta Therapeutics, NKARTA, Novartis, Orbita: Consultancy. Zeidan:Tyme: Consultancy, Honoraria; Geron: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Orum: Consultancy, Honoraria; Mendus: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; BeyondSpring: Consultancy, Honoraria; Ionis: Consultancy, Honoraria; Schrödinger: Consultancy, Honoraria; Syndax: Consultancy, Honoraria; Kura: Consultancy, Honoraria; Boehringer-Ingelheim: Consultancy, Honoraria; Shattuck Labs: Research Funding; Chiesi: Consultancy, Honoraria; Regeneron: Consultancy, Honoraria; Zentalis: Consultancy, Honoraria; Notable: Consultancy, Honoraria; ALX Oncology: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Syros: Consultancy, Honoraria; Taiho: Consultancy, Honoraria; Celgene/BMS: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Lox Oncology: Consultancy, Honoraria; Foran: Consultancy, Research Funding; Astex: Research Funding; BioCryst: Consultancy, Honoraria; Otsuka: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Novartis: Consultancy, Honoraria.

Figure 1
Figure 1
View largeDownload slide
This content is only available as a PDF.
2023
Sign in via your Institution